<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-04-11T23:32:27Z</responseDate>
  <request identifier="oai:pub.unibl.org:25679" metadataPrefix="mets" verb="GetRecord">https://pub.unibl.org/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pub.unibl.org:25679</identifier>
        <datestamp>2025-12-10T04:43:33Z</datestamp>
      </header>
      <metadata>
        <mets xmlns="http://www.loc.gov/METS/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/METS/ http://www.loc.gov/standards/mets/mets.xsd" xmlns:xlink="http://www.w3.org/1999/xlink">
          <dmdSec ID="dmd-25679">
            <mdWrap MDTYPE="DC" MDTYPEVERSION="DCMI Metadata Terms">
              <xmlData xmlns:dcterms="http://purl.org/dc/terms/">
                <dcterms:title>Efficacy and safety of ombitasvir/paritaprevir/ritonavir + dasabuvir  treatment of hepatitis C patients in Republic of Srpska</dcterms:title>
                <dcterms:creator xsi:type="dcterms:URI" title="Антонија Верхаз">https://www.unibl.org/sr-lat/fis/zaposlen/3299-antonija-verhaz</dcterms:creator>
                <dcterms:date>2017-11</dcterms:date>
                <dcterms:type>Conference Paper</dcterms:type>
                <dcterms:type>text</dcterms:type>
                <dcterms:format>24</dcterms:format>
                <dcterms:format>23</dcterms:format>
                <dcterms:identifier>/unibl/sci/idNaucniRad:18752</dcterms:identifier>
                <dcterms:relation xsi:type="dcterms:URI" title="Медицински факултет">https://med.unibl.org</dcterms:relation>
                <dcterms:relation>V kongres doktora medicine Republike Srpske sa međunarodnim učešćem</dcterms:relation>
                <dcterms:bibliographicCitation>A. Verhaz, Efficacy and safety of ombitasvir/paritaprevir/ritonavir + dasabuvir  treatment of hepatitis C patients in Republic of Srpska, pp. 23 - 24, Nov, 2017</dcterms:bibliographicCitation>
              </xmlData>
            </mdWrap>
          </dmdSec>
          <structMap>
            <div DMDID="dmd-25679"/>
          </structMap>
        </mets>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>